alan menter, m.d. - dallas dermatologistalan menter, md – cv 5 1991-1998 dermatological...

Alan Menter, MD – CV 1

…………………………………………………… Alan Menter, M.D.

CURRICULUM VITAE

DATE OF BIRTH: October 30, 1941 ADDRESS: Baylor University Medical Center (Research Unit) 3900 Junius Street, Suite 125 Dallas, TX 75246 Phone: (972) 354-7988 Fax: (972) 354-7994 E-mail: [email protected]

Baylor University Medical Center (Academic & Clinical Unit) 3900 Junius Street, Suite145 Dallas, Texas 75246 Phone: (972) 386-7546 Fax: (972) 715-1460 Email: [email protected] MARITAL STATUS: Married: Pam Menter, 12-4-66 Children (3): Keith, Colin, Kerith QUALIFICATIONS: Diplomate, American Board of Dermatology – 1978 M., B. Ch. (Rand) – 1966 M. Med. (Derm) Pretoria - 1971 EDUCATION: University of Witwatersrand, Johannesburg, South Africa,

Medical Student (1959 – 1966)

INTERNSHIPS: January – June 1967 Johannesburg General Hospital (S.A.)- Department of Medicine

July – December 1967 Johannesburg General Hospital - Department of Surgery January – June 1968

Johannesburg General Hospital - Senior Intern, Medicine and Dermatology,


RESIDENCY: Dept. of Dermatology, University of Pretoria

Pretoria (S.A.) General Hospital July 1968 – December 1971

FELLOWSHIPS: 1. Guy’s Hospital, London (1972)

2. St. John’s Hospital for Diseases of the Skin, London (1973) 3. University of Texas Southwestern Medical Center, Dallas, (1977 – 1979)

APPOINTMENTS: Consultant Dermatologist Pretoria General Hospital

December 1973 – July 1975 Associate Clinical Professor of Dermatology

University of Texas Southwestern Medical Center, Dallas, Texas, January 1977 – 1996 Medical Director, Psoriasis Center

Baylor University Medical Center, Dallas, Texas May 1979 – June 1999

Clinical Associate Professor

Department of Periodontics, Baylor College of Dentistry, Dallas, Texas, 1985 – Present Director, Fellowship Program

Baylor Psoriasis Center, Dallas, Texas 1987 – June 1999

Clinical Director

National Psoriasis Tissue Bank, Dallas, Texas May 1992 – 2000

Chief, Division of Dermatology

Baylor University Medical Center, Dallas, Texas, January 1994 – Present President-Elect, Texas Dermatological Society

May 1994 – 1995 Board of Directors, American Academy of Dermatology

May 1995 – February 1997


President, Texas Dermatological Society May 1995 – 1996

Clinical Professor of Dermatology University of Texas Southwestern Medical Center

Dallas, Texas, March 1996 – Present

Owner/Investigator, Texas Dermatology Research Institute Dallas, Texas, 2000 – 2006 Chair, Psoriasis Guidelines Committee for the American Academy of Dermatology 2007 - Present Psoriasis Chair/Investigator Baylor Research Institute Dallas, Texas 2007 – 2011 Director, Dermatology Residency Program Baylor University Medical Center Dallas, Texas, 2010 – Present Owner/Investigator, Menter Dermatology Research Institute 2011 – Present

In August, 2004, Alan Menter, MD founded the International Psoriasis Council, an international organization comprised of nine Board Members, 74 Councilors (worldwide specialty dermatologists), and other members dedicated to raising international consciousness and understanding of psoriasis as a serious autoimmune disease with major quality-of-life implications. Dr Menter served as President of the IPC from inception until December 2010. MEMBERSHIP IN: American Academy of Dermatology American Dermatological Association American Medical Association American Society for Laser Medicine & Surgery American Society of Dermatologic Surgery British Association of Dermatology Dallas County Medical Society Dallas Dermatological Society Leaders Society, Dermatology Foundation Society for Investigative Dermatology Texas Dermatological Society Texas Medical Association American Physicians Fellowship for Medicine in Israel HONORS: Texas Super Doctors, 2004 - 2012


Castle Connolly Medical Ltd. Top Doctor, 2004-Present Who’s Who in Medicine, 1996 – Present Who’s Who in the World, 1994 – Present

Best Doctors in America, 1994- Present

ICI Research Fellowship 1971 – 1973, London

OFFICES AND SERVICE POSITIONS: 1979 Secretary/Treasurer Dallas Dermatological Society 1980 President - Dallas Dermatological Society 1985 President - Dermatological Therapy Association 1986-93 Member, Medical Student Relations Committee Dallas County Medical Society 1987-89 Dallas Dermatological Society - Representative to Advisory Council American

Academy of Dermatology 1987-93 Program Coordinator, Spring and Fall Meetings, Texas Dermatological Society 1988-93 Member, Committee on Psoriasis American Academy of Dermatology 1988-93 Member, Committee on Standards of Care for Psoriasis - American Academy of

Dermatology 1989-93 Chairman, Committee on Standards of Care for Psoriasis - American Academy of

Dermatology 1989-93 Member, Council on Clinical and Laboratory Studies American Academy of

Dermatology 1990-93 Chairman, Committee on Psoriasis American Academy of Dermatology 1990-93 Director, Psoriasis Symposium Annual Program American Academy of

Dermatology 1990-94 Chairman, Task Force for Ambulatory Psoriasis Day Care Centers American

Academy of Dermatology 1991-Present Texas State Chairman, Leader's Society Dermatology Foundation


1991-1998 Dermatological Representative, Laser Committee Baylor University Medical Center 1991-1993 Member, Resource Based Relative Value Scale Committee American Academy of

Dermatology 1992-1994 Representative, Subcommittee on Joint Sponsorship - Texas Medical Association 1992-1995 Member, Research Award Review Committee Dermatology Foundation 1992-2002 Member, Leader's Society Committee Dermatology Foundation 1993-2002 Member, Medical Advisory Board National Psoriasis Foundation 1993-2004 Member, Editorial Board Journal of the American Academy of Dermatology 1994-2000 Member, Dermatology Political Action Committee (DermPac) Long-term Planning

Committee 1995-1999 Member, Guidelines Task Force Phototherapy/Photochemotherapy American

Academy of Dermatology 1996-2000 Member, International Affairs Committee American Academy of Dermatology 1996 Member, Ad Hoc Committee to draft a Patient's Bill of Rights American

Academy of Dermatology 1996-Present Founding Member, Annenberg Circle Dermatology Foundation, Research

Leadership 1997-2000 Research Chairman, National Psoriasis Foundation, Medical Advisory Board

Executive Committee 1998-2000 Member, Nominating Committee, Dermatology Foundation 1997-Present Member, Community Practitioner Advisory Board for Resident Trainees,

University of Texas Southwestern Medical Center, Dallas 1997-Present Member, Editorial Advisory Board Journal of Clinical Dermatology 1998-2004 Assistant Editor, Journal of the American Academy of Dermatology 1998-Present Editorial Board, Specialist Medicine – Dermatology 1999-2002 Member, Committee on Marketing & Image Enhancement Baylor University

Medical Center


2000-Present Editorial Board of Psoriasis Net American Academy of Dermatology 2000-Present Member, Editorial Board Practical Dermatology 2000-Present Member, Editorial Board Clinical & Experimental Dermatology 2000-Present Member, Editorial Board Journal of Dermatology for Physician Assistants 2000-Present Member, International Editorial Board, Journal of Drugs in Dermatology 2010 -Present Associate Editor, Clinical Investigation Journal 2010 -Present Member, Editorial Committee, Latin America Journal of Psoriasis and Psoriatic

Arthritis 2010 -Present Member, International Editorial Board, Dermatology and Therapy – research,

treatment and cosmetic interventions in Dermatology journal (Springer Healthcare) 2012- Present Member, Baylor Research Institute Advisory Board EXTRACURRICULAR ACTIVITIES: 1961-1968 Captain, University of Witwatersrand, Rugby Team 1961 Represented South African Universities, Cricket Team 1968 Represented South African National , Rugby Team 1969 Captain, University of Pretoria, Rugby Team 1974 Coach, University of Pretoria Rugby Team 1978-1982 Coach and Commissioner- Boys Under-12 Classic League Soccer, Dallas 1998-2003 Member, Medical Advisory Board, Gilda’s Club RESEARCH: 1972-Present Multiple clinical, investigative and drug research studies particularly relating to psoriasis

1994-2000 Director, National Gene Bank, Psoriasis


PUBLICATIONS:

1. Menter A, Snellen JW, Mitchell D. Heat regulatory studies in pachydermoperiostosis. Br J. Dermatol (Supplement) 1971; 85:7-11.

2. Menter A, Patz IM. The patter of epidermolysis bullosa in the Transvaal Bantu. Br J

Dermatol (Supplement) 1971; 85:32-36.

3. Menter A, Griessel PJC, de Klerk DJ. Giant blue nevus of the scalp with underlying scalp defect. Br J Dermatol (Supplement) 1971; 85:73-75.

4. Schultz EJ, Menter A. Treatment of discoid and subacute lupus erythematosus with

cyclophosphamide. Brit J Dermatol (Supplement) 1971; 85:60-65.

5. Menter A. Hypertrichosis lanuginose and lichenoid drug eruption due to diazoxide therapy. Proceedings of the Royal Society of Medicine 1973; 66:326.

6. Menter A, Bell AA, Wells RS. Pemphigus vulgaris in a boy aged 13. Guy’s Hospital Report

1973; 122:123-127.

7. Menter A, McKerron RA, Amos HE. Actinic reticuloid: an immunologic investigation providing evidence of basement membrane damage. Br J Dermatol 1974; 90:507-515.

8. Feinberg A, Menter A. Focal dermal hypoplasia (Goltz syndrome): case report in a male.

South African Med J 1975; 50:554.

9. Rycroft RJ, Menter A, Sharvill DE, Wells RS, Bannister LJ. Hereditary multiple glomus tumors. Transactions. St. John’s Hospital Dermatologic Society 1975; 61:70.

10. Menter A, Morrison JG. Lichen verrucosus et reticularis of Kaposi (porokeratosis striata of

Nekam): a manifestation of acquired adult toxoplasmosis. Br J Dermatol 1976: 94:645-654.

11. Menter A. The role of psoriasis day care center in the community. Dallas Med J 1980; 66:76-78.

12. Menter A. One year follow-up of 126 patients treated with combination Goeckerman-Ingram

regimen at Baylor Psoriasis Day Care Center in Dallas. Third International Psoriasis Symposium 1981; 367-368.

13. Menter A, Cram DL. The Goeckerman regimen in two psoriasis day care centers. J Am Acad

of Dermatol 1983; 9:59-65.

14. Menter A. Dermatology for the primary care physician: psoriasis. Hosp Med 1984; 21:43-72.

15. Menter A, Whiting DA, McWilliams J. Resistant childhood psoriasis: an analysis of patients seen in a day care center. Pediatr Dermatol 1984; 2:8-12.


16. Hoshaw RA, Zimmerman KG, Menter A. Ochronosis-like pigmentation fro hydroquinone

bleaching creams in American blacks. Arch Dermatol 1985; 121:105-108.

17. Blachley JD, Blankenship M, Menter A, Parker TF, Knochel JP. Uremic pruritus: skin diavalent ion content and response to ultraviolet phototherapy. Am J of Kidney Dis 1985; 5:237-261.

18. Menter A. Distinguishing psoriasis from its mimics. Contemp Ob/Gyn 1985; 26:95-103.

19. Voorhees JJ, Bohm M, Armstrong RB, Bickers DR, Cram DL, Farber EM, Harner LC,

Menter A, Roenigk HH. The role of the ambulatory psoriasis treatment center as a cost-effective program for severe psoriasis. J Am Acad Dermatol 1985; 12:740-747.

20. Menter A. Psoriasis and disorders that mimic it. Diagnosis 1985; 7:139-152.

21. Ellis CN, Horowitz SN, Menter A. Amcinonide lotion 0.1% in the treatment of patients with

psoriasis of the scalp. Current Ther Res 1988; 2:315-324.

22. Medansky RS, Bressinck R, Menter A, etal. Mometasone furoate ointment and cream 0.1% in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025% and triamcinolone acetonide 0.1%. Cutis 1988; 42:480-485.

23. Menter A, Boyd AS, Silverman AK. Guttate psoriasis and vitiligo: anatomic cohabitation. J

Am Acad Dermatol 1989; 16:698-699.

24. Boyd AS, Menter. Erythrodermic psoriasis. J Am Acad Dermatol 1989; 21:985-991.

25. Menter A. Dermatology for the primary care physician (update on psoriasis). Hosp Med 1989; 25:23-53.

26. Menter A, Boyd AS, McCaffree DL. Recurrent renal cell carcinoma presenting as skin

nodules: two case reports and review of literature. Cutis 1989; 44:305-308.

27. Ellis CN, Menter A. A randomized blinded comparison of Amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Ther Res 1989; 46:471-477.

28. Gilbert SC, Emmett M, Menter A, Silverman AK, Klintmalm G. Cyclosporine therapy for

psoriasis; serum creatinine measurements are an unreliable predictor of decreased renal function. J Am Acad Dermatol 1989; 16:470-474.

29. Silverman AK, Menter A, McCaffree DL, Sander HM. Early recognition of malignant

melanoma. BUMC 1989; 2:33-44.


30. Carroll NC, Menter A, Jones S. Acute bullous hemorrhagic eruption. Arch Dermatol 1990; 126:527-532.

31. Shultz MW, Gomez M, Hansen RC, Mills J, Menter A, Rodgers H, Judson FJ, Mertz G,

Handsfield HH. Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. Arch Dermatol 1990; 126:167-170.

32. Gilbert SC, Klintmalm G, Menter A, Silverman AK. Methotrexate-induced cirrhosis

requiring liver transplantation in three patients with psoriasis. Arch Int Med 1990; 150:889-891.

33. Menter A, Phillips CM, Silverman AK, Sander HM. Therapeutic and immunologic advances

in psoriasis. Baylor Proceedings 1990; 3:3-16.

34. Silverman AK, Gilbert SC, Watkins D, Cooper B, Menter A. Panniculitis in an immuno-compromised patient. J Am Acad Dermatol 1991; 24:912-914.

35. Nikaein A, Phillips CM, Gilbert SC, Savino D, Silverman AK, Stone MJ, Menter A.

Characterization of skin-infiltrating lymphocytes in patients with psoriasis. J Invest Dermatol 1991; 96:3-9.

36. Silverman AK, Abel EA, Menter A. Standards for education and training in phototherapy:

unanswered questions. Photodermal Photo-immunol Photomed 1991; 8:1-2.

37. Menter A, Barker JNWN. Psoriasis in practice. The Lancet 1991; 338:231-234.

38. Menter A, Morris L. Generalized pustular psoriasis. Practical Cases in Clin Dermatol 1991; 2:5-7.

39. Menter A. Molecular biology, genetics, immunology, and therapeutic modalities highlight

symposium on psoriasis. Dermatology 1991; 2:6.

40. Morris LF, Phillips CM, Binnie WH, Sander HM, Silverman AK, Menter A. Oral lesions in patients with psoriasis: a controlled study. Cutis May 1992;49(5):339-44.

41. Boyd AS, Neldner KH, Menter A. Erythema gyratum repens: a paraneoplastic eruption. J

Am Acad Dermatol 1992; 26:757-762.

42. Menter A. Hand and foot dermatoses. Practical Cases in Clin Dermatol 1992: 5:3-14.

43. Menter A. Topical therapy and cyclosporine. Psoriasis Symposium 1992; 5:3-4,7,10,13.

44. Menter A. New Zealand dermatological society holds annual meeting. Dermatology 1992; 3:7-8.


45. Silverman AK, Emmett M, Menter A. Can maintenance cyclosporine be used in psoriasis without decreasing renal function? Seminars in Dermatol 1992; 11:302-312.

46. Menter A, Rothenberg F. A rash on the hands – what could it be? Hosp Med 1993; 29:26-46.

47. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J

Am Acad Dermatol 1993; 28(3)422-425.

48. Nikaein A, Morris L, Phillips C, Soliman M, Ordonez G, Silverman A, Stone MJ, Menter A. Characterization of T-cell clones generated from skin of patients with psoriasis. J Am Acad Dermatol 1993; 28(4):551-557.

49. Drake LA, Ceilley RI, Cornelison RL, Dobes WA, Dorner W, Goltz RW, Lewis CW, Stuart

SJ, Salasche ML, Chanco Turner ML, Menter A, Skinner RB, Zanolli M, Dobes SL. Guidelines of care for psoriasis. J Am Acad Dermatol 1993; 28(4):632-637.

50. Morris LF, Harrod MJ, Menter M, Silverman AK. Methotrexate and reproduction in men:

case report and recommendations. J Am Acad Dermatol 1993 Nov; 29(5 Pt 2):913-916. Review.

51. Silverman AK, Menter A, Nemunaitis JJ, Bowcock A. Mapping genes for psoriasis: review

of a unique cooperative undertaking by the Baylor Psoriasis Center, the University of Texas Southwestern Medical Center at Dallas, and the National Psoriasis Tissue Bank. Baylor Proceedings 1994; 7(1):13-20.

52. Tomforhde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, Morris LF,

Wuepper KD, Stastny P, Menter A, Bowcock A. Gene for familial psoriasis: susceptibility mapped to the distal end of human chromosome 17q. Science 1994; 264:1141-1145.

53. Menter M. See JA, Amend WJ, Ellis CN. Krueger GG, Lebwohl M, Morison WL,

Prystowski JH, et al. Proceedings of the Psoriasis Combination and rotation therapy . J Am Acad Dermatol 1996 Feb; 34 (2PT 1):315-21

54. Menter A. Erythrodermic psoriasis: hard to diagnose but can be managed. Supplement to

Dermatology Times 1994:15(3):s9-10.

55. Menter A. The use of topical anesthetic cream (EMLA) prior to electrodessication of telangiectasia. Case History, ASTRA. Nov 1995.

56. Van Wylen DG, Baxamusa R, Berge J, Bothun K, Elvecrog JE, Eriksmoen R, Julsrud E, Fay

JM, Kelly B, Menter A, etal. Definition of ischaemia. Cardiovasc Res. 1995 May; 29(5):727.

57. Menter A, Bowcock A, Morris LF, etal. Research update: psoriasis. National Psoriasis Tissue Bank. Baylor University Medical Center Proceedings. 1995; 8(2):14.


58. Menter A. Facilitating identification of psoriasis susceptibility genes. Peer to peer: clinical highlights from the American Academy of Dermatology 53rd Annual Meeting, 1995; 7(3):20.

59. Duvic M, Moore D, Menter A, Vonderheid E. Cutaneous T-cell lymphoma in association

with silicone breast implants. J Am Acad Dermatol 1995; 32:939-42.

60. Menter A. Management considerations in psoriasis, atopic dermatitis and related dermatological conditions – short course therapy with cyclosporine. Guest Editor, Clin Drug Invest 1995; 10:51-55.

61. Silverman AK, Menter A, Hairston JL. Tars and anthralins. Dermatol Clinics 1995;

13(4):817-833.

62. Proceedings of the psoriasis combination and rotation therapy conference: Deer Valley, Utah. Editor, Menter A. J Am Acad Dermatol 1996; 34:315-21.

63. Boyd AS, Morris LF, Silverman AK, Phillips CM, Menter A. Psoriasis and pregnancy:

hormone and immune system interaction. Int J Dermatol 1996; 35(3):169-172.

64. Fernandez-Vina MA, Tomforhde J, Silverman A, Barnes R, Sang S, Young M, Lory D, Morris L, Wuepper KD, Menter A, Bowcock A, Stastny P. HLA genes in familial psoriasis vulgaris: evidence for genetic heterogeneity. Hum Immunol 1996; 40:33, suppl. 1, C-5.2.

65. Menter A. Psoriasis in primary care: diagnosis and management. Family Practice

Recertification 1997; 19:5.

66. Menter A. The use of EMLA cream and 1% lidocaine infiltration in men for relief of pain associated with the removal of genital warts by cryotherapy. J Am Acad Dermatol 1997; 37:96-100.

67. Menter A. Fighting the war against psoriasis: Know all your weapons. Derm Times 1997;

18(7):30.

68. Nguyen TQ, Young MS, Menter A. Ultraviolet B phototherapy for psoriasis. Dermatologic Therapy 1997; 4:11-23.

69. Menter A. Routine biopsies for diagnosing dermatitis discouraged. Medical Tribune Clinical

Focus. September 1997; 38:25.

70. Menter A, Niroomand F. Wounds and scars: therapeutic options. Medical Economics 1998; 3-15 March Supplement to Drug Topics.

71. Menter A. Rotational combination therapy in moderate to severe psoriasis. Highlights from

the 1997 Annual Meeting of the American Academy of Dermatology. Dermatology Direct 1998; 14-17.


72. Menter A. pathogenesis and genetics of psoriasis. Cutis 1998; 61(2S):8-10.

73. Menter A. Psoriasis: a lifelong condition that can seriously affect one’s quality of life & self esteem. PA Today 1998; 6(4):20-23.

74. Moderator: Optimizing topical retinoid treatment of psoriasis. Roundtable meeting in Dallas,

TX, January 10, 1998. Report – Suppl Skin & Allergy News, Apr 1998.

75. Bowcock A.M., Barnes R., Wilson R., Kuykendall L., Young M., Zhao C., Marcos Y., Stastny P., Cao K., Fernandez-Vian M.A., Menter A. Further evidence for psoriasis susceptibility loci on chromosomes 6p21 and 17q and evidence for novel candidate regions at 1q21-q23, 4q13-q21 and 14q31. Journal of Dermatological Science. Vol. 16, Supplement 1, March 1998; S144

76. Rodman S, Menter A. Psoriasis takes center stage in immune-mediated diseases. BUMC

Proceedings. 1998; 11:211-216.

77. Niroomand F, Menter A. Case studies. Clinical simulations in the management of dermatologic disorders. Jul 1998;4-18.

78. Menter A. When and how to use oral psoriasis therapy. Skin & Aging. Aug 1998;26-30.

79. Menter A, Guest Editor. Topical retinoid therapy for psoriasis. Psoriasis therapeutic update: a

novel topical retinoid. Highlights from a symposium held during the 22nd Hawaii Dermatology Seminar, Jan 1998.

80. Menter A, Prystowsky JH. Optimizing clinical results: tazarotene in combination with topical

corticosteroids in psoriasis. Cosmetic Dermatol 1998; 11:21-24.

81. Abrams JR, Lebwohl MB, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103:1243-1252.

82. Menter A. Topical retinoid therapy. Patient management pearls of wisdom. Current trends

held at Academy ’98, Chicago. Cutis (supplement) Mar 1999; 63:12-15.

83. Gollnick H, Menter A. Combination therapy with tazarotene plus atopical corticosteroids for the treatment of plaque psoriasis. Br J Dermatol Apr 1999; 140(Suppl 54):18-23.

84. Cooper KD, Menter A, Ritchlin CT, etal. Psoriasis: new clues to causations, new ways to

treat. Patient Care. May 1999; 33:154-164.

85. Menter A. Advances in psoriasis. Dallas Medical Journal. July 1999; 304-309.

86. Menter A, Abramovits W. Rational, sequential, and combination regimens in the treatment of psoriasis. Dermatol Therapy 1999; 11:88-95.


87. Menter A. Psoriasis: innovative therapeutic approaches for the treatment of psoriasis.

Cosmetic Dermatol Nov 1999; 12:22-24.

88. Menter A. Psoriasis: new treatments for old patches. Skin Care Today 1999; 5:14.

89. Menter A. How to manage unusual cases of psoriasis. Skin & Aging. Oct 1999; 7:44-49.

90. Abdelmalek NF, Menter MA. Marked Cutaneous “freckling” and cardiac changes. BUMC Proceedings. 1999; 12:272-274.

91. Menter A. Dermatology at Baylor University Medical Center. BUMC Proceedings. July

2000; 13:255-259.

92. Cather J, Menter A. Red-brown skin lesions and pruritus. BUMC Proceedings. July 2000;13:297-299.

93. Krueger GG, Feldman ST, Camisa C, Duvic M, Elder J, Gottlieb A, Koo J, Drueger JG,

Lebwohl M, Lowe N, Menter A, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43:281-5.

94. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol. 2000 Aug; 43(2

Pt 3):31-5. Review.

95. Cather JC, Macknett M, Menter A. Hyperpigmented macules and streaks. BUMC Proceedings. 2000; 13:405-406.

96. Cather JC, Menter A. Hair loss and plaque-like skin lesion. BUMC Proceedings. 2001;

14:101-103.

97. Menter A, Cather JC. Novel therapies for psoriasis. Am J Clin Dermatol 2002; 3(3):159-73. Review.

98. Abdelmalek N, Gerber L, Menter A. Cardiocutaneous syndromes and associations. J Am

Acad Dermatol. 2002; 46:161-83.

99. Menter A. PUVA phototherapy: Assessing and optimizing the risk/benefit ration. Skin & Allergy News (supplement) 2001; 3-14.

100. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on

quality of life: Results of a 19981 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001 Mar; 137(3):280-4.


101. Cather JC, Menter A. Diffuse eruption of pigmented papules. BUMC Proceedings. 2001; 14:185-186.

102. Cather JC, Abramovits WA, Menter A. Cyclosporine and Tacrolimus in dermatology. In

Dermatology Clinics. Norman Levine (Ed): W.B. Saunders Company, 2001; 19:119-137.

103. Cather JC, Menter A. Pruritic eruption on the chest, arms, and buttocks. BUMC Proceedings. 2001; 14:301-302.

104. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000; 43:S-31-4.

105. Bowcock A, Shannon W, Du F, Duncan J, Cao K, Aftergut K, Cather JC, Fernandez-Vina M,

Menter A. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet. 2001; 10(17):1793-1805.

106. Cather JC, Menter A. Purplish, pruritic papules on the limbs. BUMC Proceedings. 2001;

14:449-451.

107. Lebwohl M, Drake L, Menter A, Koo J, Gottlieb A, Zanolli M, Young M, McClelland P. Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 2001; 45;544-53.r

108. Cather JC, Menter A. Vesicular eruption including the mouth. BUMC. 2002; 93-94.

109. Menter A. Tazarotene in women. Guest editorial, Skin & Allergy News. Jan 2002.

110. Cather JC, Menter A, Cather J. Meandering linear pruritic lesions. BUMC Proceedings.

2002; 15:219-220.

111. Carruthers AJ, Lowe N, Menter A, Gibson J, Nordquist M, Mordaunt MS, Walker P, Eadie N. A multi-center, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002; 46:840-49.

112. Cather J, Menter A. Leg lesions and velvety hyperpigmentation on the neck. BUMC 2002;

15:327-328.

113. Koo J, Menter A, Lebwohl M, Kozma C, Slaton T, Wojcik A, Kowalski J. The relationship between quality of life and disease severity: Results from a large cohort of mile, moderate, and severe psoriasis patients. Br J Derm. 2002; 147:1078.

114. Lebwohl M, Sherer D. Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. A

randomized double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002 May; 41(5):269-74.


115. Weiss J, Menter A, Hevia O, Jones T, Ling M, Rist T, Roberts J, Shavin JS, Sklar J, Webster G, Connolly M, Furst K, Levy S. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. Aug 2002; 70:(2S)22-9.

116. Cather J, Menter A. Novel therapies for psoriasis. Review, Am J Clin Dermatol.

2002:3(3):159-73.

117. Abdelmalek NF, Gerber TL, Menter A. Cardiocutaneous syndromes and associations. CME Article, J Am Acad Dermatol. 2002 Feb; 46(2):161-83.

118. Cather J, Cather J, Menter A. Update on botulinum toxin for facial aesthetics. Dermatol Clin.

2002 Oct; 20(2002):749-76.

119. Menter A, Consultant. A guide to introducing biologic therapies for psoriasis into clinical practice. National Psoriasis Foundation. 2002.

120. Speckman RA, Wright Daw JA, Helms C, Duan S, Cao L, Taillon-Miller P, Kwok PY,

Menter A, Bowcock AM. Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet. 2003 Jan; 112(1):34-41. Epu 2002 Oct 24.

121. Speckman RA, Wright Daw JA, Helms C, Duan S, Cao L, Taillon-Miller P, Kwok PY,

Menter A, Bowcock AM. Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet 2003 Jan; 112(1):34-41.

122. Cather J, Cather J, Menter A. Psoriasiform lesions on trunk and palms. BUMC Proceedings

16; 2(2003):236-8.

123. Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, Wong WH, Bowcock AM. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics. 2003 Mar 18; 13(1):69-78.

124. Lowe NJ, Gonzalez J, Bagel J, Caro I, Ellis CN, Menter A. Repeat courses of intravenous

alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol. 2003 Mar; 42(3):224-30.

125. Cather JC, Cather JC, Menter A. Modulating T-cell responses for the treatment of psoriasis:

A focus on efalizumab. Expert Opin Biol Ther. 2003 Apr; 3(2):361-70.

126. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003 May; 48(5):760-7.


127. Menter A, Krueger G, Feldman S, Weinstein G. Psoriasis treatment 2003 at the new millennium: Position paper on behalf of the authors. J Am Acad Dermatol. 2003 Aug; 49(2):S39-S43.

128. Aly R, Fisher G, Katz I, Levine N, Lookingbill DP, Lowe N, Menter A, Morman M, Pariser

DM, Roth HL, Savin RC, Shavin JS, Stewart D, Taylor JR, Tucker S, Wortzman M. Ciclopirox gel in the treatment of patients with interdigital tinea pedis. Int J. Dermatol. 2003 Sep; 42 Suppl 1:29-35.

129. Aly R, Katz HI, Kempers SE, Lookingbill DP, Lowe N, Menter A, Morman M, Savin RC,

Wortzman M. Ciclopirox gel for seborrheic dermatitis of the scalp. Int J Dermatol. 2003 Sep; 42 Suppl 1:19-22.

130. Taylor SD, Torok H, Jones T, Lowe N, Rich P, Tschen E, Menter A, Baumann L, Wieder JJ,

Jarratt MM, Pariser D, Martin D, Weiss J, Shavin J, Ramirez N. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003 Jul; 72(1):67-72.

131. Callen J, Krueger G, Lebwohl M, McBurney E, Mease P, Menter A, Paller A, Pariser D,

Weinblatt M, Zimmerman G. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. 2003 Nov; 49(5):897-899.

132. Helms C, Cao L, Krueger JG, Wiljsman EM, Chamian F, Gordon D, Heffernan M, Daw JA,

Robarge J, Ott JL, Kwok PY, Menter A, Bowcock AM. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet. 2003 Dec; 35(4):349-356.

133. Gordon K, Papp K, Hamilton T, Walicke P, Dummer W, Li N, Bresnahan B, Menter A.

Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA. 2003 Dec 17; 290(23):3073-3080.

134. Gordon K, Vaishnaw A, O’Gorman J, Haney J, Menter A. Treatment of psoriasis with

alefacept: Correlation of clinical improvement with reductions of memory T-cell counts. Arch Derm. 2003 Dec; 139(12)1563-1570.

135. Samsula A, Menter A. Persistent rash on the face and lips. BUMC Proceedings. 2003 Oct;

16(4):488-490.

136. Lebwohl M, Menter A, Koo J, Feldman S. Case studies in severe psoriasis: A clinical strategy. J Dermatol Treat. 2003; 14 Suppl 2:26-46.

137. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: Tumor necrosis

factor alpha (TNFα) blockade in psoriasis and psoriatic arthritis. Clin Derm. 2003 Sep-Oct; 21(5):392-7.

138. Winterfield L, Cather J, Cather J, Menter A. Changing paradigms in dermatology: Nuclear

hormone receptors. Clin Derm. 2003 Sep-Oct; 21(5):447-54.


139. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW,

Menter A, Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17; 290(23):3073-80.

140. Menter A. Efficacy considerations for PUVA therapy in the biologic era. U of Kentucky:

Optimal Therapeutic Management. 2004 Jan:4.

141. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. Feb 2004; 150(2):317-26.

142. Saporito F, Menter A. Methotrexate and psoriasis in the era of new biologic agents. J Am

Acad Dermatol. 2004 Feb; 50(2):301-09.

143. Menter A. Understanding and using the new biologics. Skin & Aging. 2004 Feb; Suppl 4-5.

144. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004 Mar; 50(3):416-30.

145. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE. Impact of efalizumab on

psoriasis-specific patient-reported outcomes: Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004; 3(1):27-38.

146. Gottlieb AB, Kang S, Linden KG, Lebwohl M, Menter A, Abdulghani AA, Goldfarb M,

Chieffo N, Totoritis MC. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol. 2004 Apr; 111(1):28-37.

147. Menter A. Rationale for the use of topical corticosteroids in melasma. J Drugs Dermatol.

2004 Mar/Apr; 3(2):169-74.

148. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. JAAD 2004 Jun; 50(6):859-66.

149. Koo J, Gottlieb A, Lebwohl MG, Menter A, Wolf J. Topical psoriasis update: Today’s

topical treatment strategies to optimize patient response and quality of life. Dermatology Times 2004 Jun; 25(6): CME Supplement 1-15.

150. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, De La Brassinne M,

Ferrandiz C, Griffiths C, Katsambas A, Kragballe K, Lynde C, Menter A, Ortonne JP, Papp K, Prinz J, Rzany B, Ronnevig J, Saurat JH, Stahle M, Stengel FM, Van De Kerkhof P, Voorhees J. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004 Aug; 151 Suppl 69:3-17.


151. Leonardi C, Menter A. Biologic Agents for Psoriasis: A close look at the latest data. Skin &

Allergy News 2004 Aug; CME Suppl.

152. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano C, Menter A. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004 Oct; 51(4):534-42.

153. Menter A. The effect of psoriasis on patients’ quality of life and improvements associated

with alefacept therapy. J Cutan Med Surg 2004 Dec; 8 Suppl 2:20-5.

154. Winterfield LS, Menter A. Infliximab. Dermatol Ther 2004 Nov; 17:(5)409-26.

155. Winterfield L, Menter A. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. Dermatol Clin. 2004 Oct; 22:(4)437-47,ix.

156. Riddle C, Young M, Menter A. Practical considerations in future psoriasis therapies.

Dermatol Clin 2004; 22:487-492.

157. Menter A, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol 2004; 21:87-88.

158. DiGiovanna JJ, Langman CB, Tschen EH, Jones T, Menter A, Lowe NJ, Eichenfield L,

Hebert AA, Pariser D, Savin RP, Smith SR, Jarratt M, Rodriguez D, Chalker DK, Kempers S, Ling M, Rafal ES, Sullivan S, Kang S, Shah LP, Wu E, Newhouse J, Pak J, Eberhardt DR, Bryce GF, McLane JA, Ondovik M, Chin C, Khoo K, Rich P. Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol 2004 Nov; 51(5):709-717.

159. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, Zaias N, Chen DM,

Parneix-Spake A, Hultsch T, Menter A. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized Study. J Am Acad Dermatol 2004 Nov; 51(5):731-8.

160. Gleaves TR, Cather JC, Menter A. Oral erosions and cutaneous bullae. BUMC Proceedings

Jan 2005; 18(1):71-73.

161. Menter A. The Blue Journal 25 years ago. JAAD Jan 2005; (52) 1:88.

162. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W for the Efalizumab Study Group. Efficacy and safety observed during 24 weeks of Efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005 Jan; 141(1):31-8.


163. Gordon K, Feldman SR, Koo JYM, Menter A, Rolstad T, Krueger G. Editorial: Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005 Jan; 141(1):82-84.

164. Menter A, Cather JC. Alefacept. Therapy 2005 Jan; 2(1):23-35.

165. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton

PG, Gottlieb AB for the Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: Results for a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33.

166. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging

directed therapies. Ann Rheum Dis. 2005 Mar; 64(Suppl II):ii87- ii90.

167. Mease P, Boehncke W-H, Gladman DD, Menter A. Discussion: Treatment of psoriatic arthritis and psoriasis. Ann Rheum Dis. 2005 Mar; 64(Suppl II):ii91-ii92.

168. Gladman DD, Menter A. Introduction/overview on clinical registries. Ann Rheum Dis 2005

Mar; 64(Suppl II):ii101- ii102.

169. Cather JC, Menter A. Efalizumab: continuous therapy for chronic psoriasis. Expert Opin Biol Ther. Mar 2005; 5(3):393-403.

170. Menter A. Ciclosporin in psoriasis consensus statement. Br J Dermatol. 2005

Apr;152(4):811; author reply 811.

171. Shalita A, Miller B, Menter A, Abramovits W, Loven K, Kakita L. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: A multicenter, double-blind, randomized, parallel-group study. J Drugs in Derm. Mar/Apr 2005; 4(2):153-158.

172. Cather JC, Menter A. Combining traditional agents and biologics for the treatment of

psoriasis. Semin Cutan Med Surg Mar 2005; 24(1):37-45.

173. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial. Br J Derm May 2005; 152:954-960.

174. Feldman SR, Koo JYM, Menter A, Bagel J. Decision points for the initiation of systemic

treatment for psoriasis. J Am Acad Dermatol 2005 Jul; 53(1):101-7.

175. Torok H, Taylor S, Baumann L, Jones T, Wieder J, Lowe N, Jarret M, Rich P, Pariser D, Tschen E, Martin D, Menter A, Weiss J. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of Triple Combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs in Derm. Sep/Oct 2005; 4(5):592-7.


176. Abramovits W, Cockerell C, Stevenson LC, Goldstein AM, Ehrig T, Menter A. PsEma – A

hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema. SKINmed 2005 Sep/Oct; 4(5):275-81.

177. Helms C, Saccone NL, Cao L, Daw JA, Cao K, Hsu TM, Taillon-Miller P, Duan S, Gordon

D, Pierce B, Ott J, Rice J, Fernandez-Vina MA, Kwok PY, Menter A, Bowcock A. Localization of PSORS1 to a haplotypes block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet 2005 Dec; 118(3-4):466-76.

178. Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. The efficacy of multiple

courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006 Jan; 54(1):61-3.

179. Mease PJ, Menter MA. Quality of Life issues in psoriasis and psoriatic arthritis: Outcome

measures and therapies from a dermatology perspective. J Am Acad Dermatol 2006 Apr; 54(4):685-704.

180. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC,

Toth D. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006 Apr; 54(4 Suppl 1):S171-81. Review.

181. Menter A, Leonardi CL, Sterry W, Bos JD, Papp KA. Long-term management of plaque

psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 2006 Apr; 54(4 Suppl 1):S182-8. Review.

182. Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA,

Wang X, Menter A, the Efalizumab Study Group. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial. Int J Dermatol. 2006 May; 45(5):605-614.

183. Li LY, Brimhall AK, Menter A. Systemic therapy for moderate-to-severe psoriasis. Expert

Rev Dermatol 2006; 1(1):77-92

184. Gordon KB, Langley RG, Leonardi D, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 Oct; 55(4):598-606.

185. Lowe N, Horwitz S, Tanghetti E, Draelos Z, Menter A. Tazarotene versus tazarotene plus

hydroquinone in the treatment of photodamaged facial skin: A multicenter, double-blind, randomized study. J Cosmet Laser Ther. 2006 Sep; 8(3):121-7.

186. Leonardi CL, Toth D, Cather JC, Langley RGB, Werther W, Compton P, Kwon P, Wetherill

G, Curtin F, Menter A. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006; 213:204-214.


187. Menter A. Recent advances in psoriasis therapy and the work of the International Psoriasis

Council. US Derm Review 2006; 1:23-27.

188. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 Jan; 56(1):31.e1-e15.

189. Griffiths CEM, Christophers E, Barker JNWN, Chalmers RJG, Chimenti S, Krueger GG,

Leonardi C, Menter AM, Ortonne JP, Fry L. A classification of psoriasis according to phenotype. Br J Dermatol 2007 Feb; 156:258-262.

190. Lebwohl M, Menter A, Weiss J, Clark SD, Flores J, Powers J, Balin AK, Kempers S, Glinert

RJ, Fleming T, Liu Y, Graeber M, Pariser DM. Calcitriol 3µG/G ointment in the management of mild to moderate plaque type psoriasis: Results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007; 6(4):428-35.

191. Veraldi S, Menter A, Innocenti M. Treatment of mild to moderate seborrhoeic dermatitis

with MAS064D (Sebclair®), a novel topical medical device. Results of a pilot, randomized, double-blind, controlled trial. JEADV 2007.

192. Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, et al.

Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, phase IIIb study. Int J Dermatol 2007; 46:637-648.

193. Schlessinger J, Menter A, Gold M, Leonardi C, Eichenfeld L, Plott RT, et al. Clinical Safety

and Efficacy Studies of a Novel Formulation Combining 0.025% Tretinoin and 1.2% Clindamycin Phosphate. J Drugs Dermatol 2007;

194. Sterry W, Strober BE, Menter A, on behalf of the International Psoriasis Council. Obesity in

psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007 Oct;157(4):649-55

195. Koo J, Menter A, Feldman S, Lebwohl M. The COBRA Trial: A Large-Scale Community-

Based Trial on Moderate and Severe Psoriasis. Cutis 2007 Nov Vol.80 5S

196. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet.2007 Jul 21;370(9583):272-84

197. Menter, A. Topical Monotherapy With Clobetasol Propionate Spray 0.05% Added to Other

Stable Treatments: Add-on Therapy in the COBRA Trial. Cutis 2007 Nov Vol.80 5S

198. Van de Kerkhof PCM, Barker J, Griffiths CEM, Kragballe K, Mason J, Menter A, Papp K. Psoriasis: consensus on topical therapies. J Eur Acad Dermatol Venereol 2007;Dec 13 [Epub ahead of print]


199. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley, RG, Strober BE, Kaul

M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15

200. Perlmutter A, Cather J, Franks B, Jaracz, E, Menter A. Alefacept revisited. Our 3-year

clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008;58:116-24

201. Revicki DA, Willian MK, Menter A, Saurat J-H, Harnam N, Kaul M. Relationship between

Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis. Dermatology 2008;216:260-270

202. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and

Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Arch Dermatol Feb 2008; 144(2):200-07

203. Lebwohl M, Strober B, Sobell J, Menter A, Chen Y, Caro I, Leonardi C. Efficacy and Safety

of Efalizumab in Psoriatic Patients ≥ 200 Pounds. Arch Dermatol Feb 2008

204. Menter, A. Ps treatment: New Insights and Emerging Clinical Data. Feb 4 2008, vol 1 No 1

205. Liu YC, Helms, C, Liao W, Zaba LC, Duan S, Gardner J, Wise C, Miner A, Malloy MJ, Pullinger , Kane J, Saccone S, Worthington J, Bruce I, Kwok PY, Menter A, Krueger J, Barton A, Saccone NL, Bowcock AM. A genome-wide association study of psoriasis and psoriatic arthritis identifies new loci. PLoS Genetics March 2008,vol 4(3): Epub 41-55

206. Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang Y-C, Chiou C-F, Dann F,

Stevens SR. Utilization of Narrow-Band Ultraviolet Light B Therapy and Etanercept for the Treatment of Psoriasis (UNITE): Efficacy, Safety, and Patient-Reported Outcomes. J Drugs Dermatol 2008; 7(3):245-53

207. Menter A, Gottlieb A, Feldman S, Van Vorhees AS, Leonardi CL, Gordon KB, Lebwohl M,

Koo JYM, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol May 2008; 58(5):826-50

208. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JYM, Van Vorhees AS,

Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol May 2008; 58(5):851-64


209. Smith EC, Riddle C, Menter MA, Lebwohl M. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008 May;47(5):514-8

210. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: results of a 3-

year continuous dosing study for long-term control of psoriasis. Br J Dermatol May 2008; 158:1107-16

211. Menter A, Vamvakis G, Jorizzo J. One-Week Treatment With Once-Daily Fluorouracil

Cream 0.5% in Participants With Actinic Keratoses. Cutis. 2008; 81:509-516

212. Gordon KB, Blum RR, Papp KA, Matheson R, Bolduc C, Hamilton T, Heffernan M, Menter A, Okun M, Zhong J, Kaul M, Camez A. Efficacy and Safety of AdalimumabTreatment in Patients with Moderate to Severe Psoriasis: A double-Blind, RandomizedClinical Trial. Psoriasis Forum, 2008 vol 13(1):4-12

213. Reich K, Menter A, Plotnick M, Guzzo C, Li S, Gottlieb A. Consistency of

InfliximabResponse Across Subgroups of Patients with Psoriasis: Integrated Results From Randomized Clinical Trial. Psoriasis Forum, 2008 vol 13(1): 21-33

214. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of

alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta analysis of randomized controlled trials. Br J Dermatol 2008; pg 274-85

215. Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter

A. Infliximab improves heath-related quality of life in the presence of Comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008 September 159(3):707-710

216. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol,

2008 Jun;7(6):563-72

217. Kourosh S, Miner A, Menter A. Psoriasis as the Marker of Underlying Systemic Disease. Skin Therapy Letter, vol13, #1, Feb 2008

218. Warren RB, Chalmers RJG, Griffiths CEM, Menter A. Methotrexate for psoriasis in the era

of biological therapy. Clin Exp Dermatol,2008, 33, 551-554

219. Hamilton T, Menter A, Caro I, Compton P, Sobell J, Papp KA. Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open- Label Extension of a Phase IIIb Trial. Drug Saf. 2008;31(8):715-26.

220. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, Menter A, van de

Kerkhof PCM. Psoriasis: Improving adherence to topical therapy. J Am Acad Dermatol 2008, 59(6):1009-16

221. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab

improves health- related quality of life in patients with moderate to severe plaque psoriasis


compared with the United States general population norms: Results from a randomized,controlled Phase III study. Health Qual Life Outcomes. 2008, 6:75 doi:10.1186/1477-7525-6-75.

222. Strober BE, Menter A, Crowley J. Long-term safety and efficacy in the treatment of psoriatic

conditions. Practice with The Experts, Vol 2(4), Dec 1 2008

223. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009 160:8-15

224. Nair RP, Duffin Callis K, Helms , Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y,

Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Lioa W, Kwok P-Y, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR for the Collaborative Association Study of Psoriasis. Genome-wide scan reveals association of Psoriasis with IL-23 and NF-κB pathways. Nat Genet41:199-204, 2009.

225. Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu M-C, Guzzo C, Diels J, Gelfand JM.

Adverse drug events in infliximab-treated patients compared with the general psoriasis Population. J Drugs Dermatol, Dec 2008;7(12):1137-46

226. Gottlieb A, Menter A, Mendelsohn A, Shen Y-K, Li S, Guzzo C, Fretzin S, Kunynetz R,

Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet,

227. Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW. Comparing Clobetasol,

Propionate 0.05% Spray to Calcipotriene 0.005% Betamethasone Dipropionate 0.064% Ointment for the Treatment of Moderate to Severe Plaque Psoriasis J Dr Dermatol 2009 Jan;8(1):52-7

228. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo

JY, Lebwohl M, Lim HW, Van Vorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; April;60(4):643-59

229. Ul Ain Kamili Q, Menter A. Psoriasis in the Pediatric Patient. Pediatric Society of Greater

Dallas, First Quarter, Feb 2009, Pg 10-14

230. Boltan, LE, Menter A. Pustules and dystrophy of the nails. BUMC Proceedings - Dermatology Report, April 2009, 162-163

231. Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical

review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009 Jun; 60(6):1024-31


232. Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ,

Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young MA. Series of critically challenging case scenarios in moderate to severe psoriasis:A Delphi consensus approach. J Am Acad Dermatol July 2009; 61(1): S1,pg 1-46

233. Menter A, ul Ain Kamili Q, Farley E. Get under the skin – diagnosis and treatment of

psoriasis and guidelines for specialists. Medical Economics, July 2009

234. Miner A, Menter A. The ethics of consulting with pharmaceutical companies. Clinics in Dermatology (2009) 27, 339-345

235. Larsen F, Menter A, Cockerell CJ, Wilcox BN. Verrucous linear (segmental) psoriasis of the

right leg responding to radiation therapy. J Drugs Dermatol 2008 Oct;7(10):969-71

236. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Honigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD,Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. JEADV Oct 2009, vol 23, Supplmt 2

237. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo

JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermato 2009 Sep;61(3):451-85

238. ul Ain Kamili Q, Menter A. Atypical presentation of histoplasmosis in a patient with

psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol Jan 2010;9(1):57-90

239. ul Ain Kamili Q, Menter A. Genetics of psoriasis and psoriatic arthritis. Psoriasis Forum, vol

15, No 1: 8-12

240. Tebbey P, Romiti R, Prens E, Menter A. The International Psoriasis Council Presents Top 2009 Research Articles. Psoriasis Forum, vol 15, No 2:24-32

241. Hollmig T, Menter A. Familial coincidence of hidradenitis suppurativa and steatocystoma

Multiplex. Clin and Exp Dermatol 2009 Nov 3

242. Menter A, Korman NJ, Elmets CA, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009 Apr; 60 (4):643-59


243. Horn EJ, Chambers CD, Menter A, Kimabll A; IPC. Pregnancy outcomes in psoriasis: why

do we know so little? J Am Acad Dermatol 2009 Aug;61(2):e5-8

244. Menter A, Korman NJ, Elmets CA, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009 Sep; 61(3):451-85

245. Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis.

Cutis. 2009 Oct;84(4 Suppl):14-24.

246. ul Ain Kamili, Menter A. Topical treatment of psoriasis. Curr Probl Dermatol. Karger 2009 vol 38, pp 37-58

247. Griffiths CEM, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C,

Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A (ACCEPT study group). Comparison of ustekinumab and etanercept for moderate-to severe psoriasis. N Engl J Med Jan 14, 2010 362;2:118-28

248. Menter A, Augustin M, Signorovitch J, Yu A, Wu E, Gupta SR, Bao Y, Mulani P. The effect

of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010,e-pub March 8

249. Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune diseases.

Expert Opin Biol Ther 2010;10(4)

250. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med and Surg March 2010; 29(1):10-15

251. Kavanaugh A, Menter A, Shen Y-K, Lee S, Mendelsohn A, Gottlieb A. Ustekinumab

improves physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Current Medical Research and opinion

252. Menter A, Gordon K, Leonardi C. Efficacy and safety of adalimumab across subgroups of

patients with moderate to severe psoriasis.. J Amer Acad Dermatol Sept 2010;63(3):

253. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu M-C, Ortonne JP, Gordon K, Kimball A. Ustekinumab significantly improves symptoms of anxiety, depression, and skin- related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Amer Acad Dermatol Sept 2010;63(3):

http://links.mkt1691.com/ctt?kn=24&m=35691499&r=MzE1MDg2OTY4OAS2&b=0&j=Nzk1NzY2NTIS1&mt=1&rt=0




254. Zeichner J, Lebwohl M, Menter A, Bagel J, DelRosso J, Elewski B, Feldman S, Kircik L, Koo J, Stein Gold L, Tanghetti E. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis, 2010 Sep;vol 86: 3S

255. Menter A, Griffiths CEM, Tebbey PW, Horn EJ, Sterry W on behalf of the International

Psoriasis Council. Exploring the association between cardiovascular and other disease related risk factors in the psoriasis population: the need for increased understanding across the medical community. JEADV 2010

256. Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: Part I. J Amer Acad

Dermatol Dec 2010 63(6):925-46

257. Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: Part II. J Amer Acad Dermatol Dec 2010 63(6):949-72

258. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo

YM, Lebwohl M, Leoanrdi CL, Lim HW, Van Vorhees AS, Beutner KR, Ryan C, Bhuhsan Guidelines of care for the treatment of psoriasis and psoriatic arthritis: section 6. Case-based presentations and evidence-based conclusions. J Amer Acad Dermatol July 2011 65(1):137-74

259. Ryan C, Menter A, Warren RB. The latest advances in pharmacogenetics and

pharmacogemonics in the treatment of psoriasis. Mol Diagn Ther. 2010 Apr 1;14(2):81-93.

260. Menter A, Sofen H, Smith S, Papp K, Kempers S, Hudson CP, Colón LE, Johnson LA, Gottschalk R. An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis. Cutis. 2011 Jul;88(1):46-51

261. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de

Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24;306(8):864-71.

262. van de Kerkhof P, Barker J, Griffiths CE, Menter A, Leonardi C, Young M, Kemeny L,

Pincelli C, Bachelez H, Katsambas A, Ståhle M, Horn EJ, Sterry W; International Psoriasis Council. Improving clinical trial design in psoriasis: Perspectives from the global dermatology community. J Dermatolog Treat. 2011 Aug;22(4):187-93. Epub 2010 Oct 1.

263. Joyce CE, Zhou X, Xia J, Ryan C, Thrash B, Menter A, Zhang W, Bowcock AM. Deep

sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet. 2011 Oct 15;20(20):4025-40. Epub 2011 Aug 1.

264. Wittkowski KM, Leonardi C, Gottlieb A, Menter A, Krueger GG, Tebbey PW, Belasco J,

Soltani-Arabshahi R, Gray J, Horn L, Krueger JG; International Psoriasis Council. Clinical

http://www.ncbi.nlm.nih.gov/pubmed/21862748









symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One. 2011;6(6):e20279. Epub 2011 Jun 1.

265. Kamili QU, Miner A, Hapa A, Menter A. Infliximab treatment for psoriasis in 120 patients

on therapy for a minimum of one year: a review. J Drugs Dermatol. 2011 May;10(5):539-44

266. Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol. 2011 Feb;146(1):9-15. Review.

267. Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J; ABT-874 Study

Investigators. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol. 2011 Feb;64(2):263-74. Epub 2010 Dec 9.

268. Roberson ED, Liu Y, Ryan C, Joyce CE, Duan S, Cao L, Martin A, Liao W, Menter A, Bowcock AM

A subset of methylated CpG sites differentiate psoriatic from normal skin.. J Invest Dermatol. 2012 Mar;132(3 Pt 1):583-92. doi: 10.1038/jid.2011.348. Epub 2011 Nov 10

269. Hudson CP, Kempers S, Menter A, Papp K, Smith S, Sofen H, Colón LE, Johnson LA, Gottschalk R.

An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis. Cutis. 2011 Oct;88(4):201-7.

270. Strober BE, Armour K, Romiti R, Smith C, Tebbey PW, Menter A, Leonardi C. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol. 2012 Feb;66(2):317-22

271. Abramson A, Menter A. An unusual facial ulcer. Proc (Baylor Univ Med Cent). 2012

Jan;25(1):85-6

272. Dhaliwal S, Patel M, Menter A. Secondary syphilis and HIV. Proc (Baylor Univ Med Cent). 2012 Jan;25(1):87-9

273. Heller MM, Wong JW, Nguyen TV, Lee ES, Bhutani T, Menter A, Koo JYQuality-of-life

instruments: evaluation of the impact of psoriasis on patients.. Dermatol Clin. 2012 Apr;30(2):281-91, ix.

274. Ryan C, Abramson A, Patel M, Menter A. Current investigational drugs in psoriasis. Expert

Opin Invest Drugs. 2012 Apr;21(4):473-87

275. Menter A. Response to the letter to editor re:”Methotrexate and psoriasis: consensus conference”. J Am Acad Dermatol. 2012 Apr;66(4):689; author reply 689-90

276. Papp K, Menter A, Poulin Y, Gu Y, Sasso EH. Long-term outcomes of interruption and retreatment

vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol. 2012 Mar 16. Epub ahead of print.









http://www.ncbi.nlm.nih.gov/pubmed?term=Hudson%20CP%5BAuthor%5D&cauthor=true&cauthor_uid=22106730

http://www.ncbi.nlm.nih.gov/pubmed?term=Kempers%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22106730

http://www.ncbi.nlm.nih.gov/pubmed?term=Menter%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22106730

http://www.ncbi.nlm.nih.gov/pubmed?term=Papp%20K%5BAuthor%5D&cauthor=true&cauthor_uid=22106730

http://www.ncbi.nlm.nih.gov/pubmed?term=Smith%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22106730

http://www.ncbi.nlm.nih.gov/pubmed?term=Sofen%20H%5BAuthor%5D&cauthor=true&cauthor_uid=22106730

http://www.ncbi.nlm.nih.gov/pubmed?term=Col%C3%B3n%20LE%5BAuthor%5D&cauthor=true&cauthor_uid=22106730

http://www.ncbi.nlm.nih.gov/pubmed?term=Johnson%20LA%5BAuthor%5D&cauthor=true&cauthor_uid=22106730

http://www.ncbi.nlm.nih.gov/pubmed?term=Gottschalk%20R%5BAuthor%5D&cauthor=true&cauthor_uid=22106730


http://www.ncbi.nlm.nih.gov/pubmed?term=Strober%20BE%5BAuthor%5D&cauthor=true&cauthor_uid=22243723

http://www.ncbi.nlm.nih.gov/pubmed?term=Armour%20K%5BAuthor%5D&cauthor=true&cauthor_uid=22243723

http://www.ncbi.nlm.nih.gov/pubmed?term=Romiti%20R%5BAuthor%5D&cauthor=true&cauthor_uid=22243723

http://www.ncbi.nlm.nih.gov/pubmed?term=Smith%20C%5BAuthor%5D&cauthor=true&cauthor_uid=22243723

http://www.ncbi.nlm.nih.gov/pubmed?term=Tebbey%20PW%5BAuthor%5D&cauthor=true&cauthor_uid=22243723


http://www.ncbi.nlm.nih.gov/pubmed?term=Leonardi%20C%5BAuthor%5D&cauthor=true&cauthor_uid=22243723



http://www.ncbi.nlm.nih.gov/pubmed?term=Heller%20MM%5BAuthor%5D&cauthor=true&cauthor_uid=22284142

http://www.ncbi.nlm.nih.gov/pubmed?term=Wong%20JW%5BAuthor%5D&cauthor=true&cauthor_uid=22284142

http://www.ncbi.nlm.nih.gov/pubmed?term=Nguyen%20TV%5BAuthor%5D&cauthor=true&cauthor_uid=22284142

http://www.ncbi.nlm.nih.gov/pubmed?term=Lee%20ES%5BAuthor%5D&cauthor=true&cauthor_uid=22284142

http://www.ncbi.nlm.nih.gov/pubmed?term=Bhutani%20T%5BAuthor%5D&cauthor=true&cauthor_uid=22284142


http://www.ncbi.nlm.nih.gov/pubmed?term=Koo%20JY%5BAuthor%5D&cauthor=true&cauthor_uid=22284142



277. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB,

Thompson EH, Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012 Mar 29;366(13):1181-9

278. Kragballe K, Menter A, Lebwohl M, Tebbey PW, van de Kerkhof PC, International Psoriasis

Council. Long-term management of scalp psoriasis: perspectives from the international psoriasis council. J Dermatol treat 2012 Jun 5 (Epub ahead of print)

279. Menter A. Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque

psoriasis. Cutis. 2012 Feb;89(2):89-94

280. Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol. 2012 Apr;147(2):179-87

281. Wofford J, Patel M, Readinger A, Menter A. Widespread dermal ulcerations and bullae. Proc

(Baylor Univ Med Cent). 2012 Apr;25(2):155-8

282. Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, Ryan C, Duan S, Helms CA, Liu Y, Chen Y, McBride AA, Hwu WL, Wu JY, Chen YT, Menter A, Goldbach-Mansky R, Lowes MA, Bowcock AM. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012 May 4;90(5):784-95

283. Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D,

Hayashi G, Olfson EH, Feng BJ, Pullinger CR, Kane JP, Wise CA, Goldbach-Mansky R, Lowes MA, Peddle L, Chandran V, Liao W, Rahman P, Krueger GG, Gladman D, Elder JT, Menter A, Bowcock AM. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet. 2012 May 4;90(5):796-808.

284. Menter A, Thrash B, Cherian C, Matherly LH, Wang L, Gangiee A, Morgan JR, MaedaDY, Schuler

AD, Kahn SJ, Zebala JA. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J Pharmacol Exp Ther. 2012 Sep;342(3):696-708.

285. Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha

inhibitory agents: A review and recommendations for management. J Am Acad Dermatol. 2012 Jun 21. [Epub ahead of print]

286. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan

H, Harness JA. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012 Sep;167(3):668-77

287. Menter, A. Psoriasis and Psoriatic Arthritis: Similarities and Differences. Value-Base Care in

Rheumatology, Sept 2012.

288. Menter A, Caveney S, Gottschalk RW. Impact of Clobetasol Propionate 0.05% Spray on

Health-Related Quality of Life in Patients with Plaque Psoriasis. J Dr Dermatol 2012 Nov; 11(11):1348-1353







289. Lloyd P, Ryan C, Menter A. Psoriatic arthritis: a review. Arthritis. Vol 2012

290. Corey K, Mattei P, Houston N, Tebbey PW, Menter A, van de Kerkhof PCM, Kimball AB. Psoriasis, a proof-of-principle condition for immune-mediated inflammatory disorders: perspectives toward optimal clinical trial design. Clin. Investing. 2012;2(7):671-78

291. Paller A, Mercy K, Kwasny M, Choon S, Cordoro K, Girolomoni G, Menter A, Wynnis T,

Mahoney A, Oostveen A, Marieke S. Association of Pediatric Psoriasis Severity with Excess and Central Adiposity: An International Cross-Sectional Study. Arch Dermatolo, Vol 148, Nov 2012

292. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690, 550) An Oral Janus Kinase

Inhibitor, Improves Patient-Reported Outcomes in a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Moderate-to-Severe Psoriasis. J Eur Acad Dermatol Venereol, 2013 Jan 7 (Epub ahead of print)

293. Shah K, Boland R, Patel M, Thrash B, Menter A, Cutaneous Manifestations of

Gastrointestinal Disease, Part I. JAAD, Vol. 68, Issue 2, Feb. 2013

294. Thrash B, Patel M, Shah K, Boland R, Menter A, Cutaneous Manifestations of Gastrointestinal Disease, Part II. JAAD, Vol. 68, Issue 2, Feb. 2013

295. Mercy K, Kwasny M, Cordoro KM, Menter A, Tom WL, Korman N, Belazarian L,

Armstrong AW, Levy ML, Paller AS. Clinical Manifestations of Pediatric Psoriasis: Results of a Multicenter Study in the United States. Pediatr Dermatol. 2013 Jan 30

296. Patel M, Day A, Warren R, Menter A. Emerging Therapies for the Treatment of Psoriasis,

Dermatol Ther (Heidelb) 2012 Dec;2(1):16

297. Paller A, Mercy K, Kwasny M, Choon S, Cordoro K, Girolomoni G, Menter A, Wynnis T, Mahoney A, Oostveen A, Marieke S. Association of Pediatric Psoriasis Severity with Excess and Central Adiposity: An International Cross-Sectional Study. JAMA Dermatol/Vol. 149 (No.2), Feb 2013, 166-176

298. Menter A., Beyond the Skin: What Comorbidities Teach us About Understanding And

Treating Psoriasis. Practical Dermatology, December 2012, 22-28.

299. Kimball AB, Pariser D, Yamauchi PS, Menter A, Teller CF, Shi Y, Yong M, Creamer K, Hooper M, Aras G, Kricorian G, Gelfand JM. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol, May 2013; 68(5): 756-64


LETTERS TO THE EDITOR: 1. Primary care physicians performing biopsy procedures. Arch Int Med. 1986; 106:416. 2. Symmetrical purpura doesn’t mirror child abuse. JAMA. 1987; 257:486. 3. Cystic acne in psoriatic patients undergoing etretinate therapy. J Am Acad Dermatol. 1988;

18:751-2. 4. Methotrexate and psoriasis. JAMA. 1988; 26:3005. 5. Occlusion of potent topical steroids. Arch Dermatol. 1995; 131:226-7. 6. Topical calcipotriene ointment and etretinate: Another combination therapy for psoriasis

vulgaris. J Am Acad Dermatol. 1997; 36(5):803. 7. PUVA and psoriasis. Cosmetic Dermatol. July 1998; 11:13. 8. Elevate, not relegate, dermatology. Derm Times. March 2003; 24(3):6. 9. Supernumerary nipple and Cardiocutaneous associations: Reply. J Am Acad Dermatol. June

2004; 50:6(e2). 10. Ciclosporin in psoriasis consensus statement. BJD. Apr 2005; 152(4):811.

11. Rethinking eligibility creep. JAAD July 2008;59(1):165-167

12. Goeckerman therapy vs biologics in the treatment of psoriasis. JAAD March 2010;62(3):516-

17 BOOK CHAPTERS: 1. “Psoriasis” in Conn’s Current Therapy, Robert E. Rakel, Editor, 1985; 680-83. 2. “Psoriasis Day Care Centers” in Practical Psoriasis Therapy, Nicholas J. Lowe, Editor. 1986;

116-117. 3. “Phototherapy and Photochemotherapy in the Psoriasis Day Care Setting” in Phototherapy in

Dermatologic Practice, Elizabeth Abel, Editor. 1992 4. “Psoriasis Day Care Centers” in Practical Psoriasis Therapy, Second Edition, Nicholas J.

Lowe, Editor. 1992. 5. “Genes in Psoriasis” in Psoriasis, Third Edition, Dr. H. Roenigk, Jr. and Dr. Howard I.

Maibach, Editors. 1998.


6. “Combination Therapies: Dovonex & Phototherapy” in Psoriasis, Third Edition, Dr. H. Roenigk, Jr. and Dr. Howard I. Maibach, Editors. 1998.

7. “Papulosquamous Diseases” in Conn’s Current Therapy, Second Edition, Robert E. Rakel,

MD, Editor. W.B. Saunders Company. 1999. 8. “Combination Therapy with Vitamin D-UVB and PUVA” in Psoriasis, Third Edition, Dr. H.

Roenigk, Jr. and Dr. Howard I. Maibach, Editors. 1999. 9. “An Overview of Psoriasis” in Therapy of Moderate-to-Severe Psoriasis, Second Edition,

Gerald D. Weinstein and Alice B. Gottlieb, Editors. 2003: 1-28. 10. “The Pathogenesis and Treatment of Psoriasis” in REDI, Making a Difference in

Rheumatology: Early and Aggressive Treatment = Better Outcomes for Today’s Patients, Michael H. Schiff, MD, Editor, 2003.

11. “The Koo-Menter Psoriasis Instrument for Identifying Candidate Patients for Systemic

Therapy” in Mild to Moderate Psoriasis, John Y.M. Koo, Mark G. Lebwohl, and Chai Sue Lee, Editors. 2006: 9-28.

12. “Summary of Therapeutic Options for Mild-to-Moderate Psoriasis” in Mild to Moderate

Psoriasis, John Y.M. Koo, Mark G. Lebwohl, and Chai Sue Lee, Editors. 2006: 243-261.

13. “An overview of psoriasis” in Therapy of Moderate to Severe Psoriasis, G. Weinstein, Alice Gottlieb, 3rd edition – in press

14. “Efalizumab in the treatment of psoriasis” in Therapy of Moderate to Severe Psoriasis, G.

Weinstein, Alice Gottlieb 3rd edition – in press

15. “An overview of psoriasis” in Moderate-to-severe psoriasis”, 3rd edition, Koo J, Menter A

16. “Efalizumab in the treatment of psoriasis” in Moderate-to-severe psoriasis”, 3rd edition, Koo J, Menter A

17. “Introduction” in The Psoriasis and Psoriatic Arthritis Pocket Guide,3rd edition, Van Vorhees

A, Feldman S, Koo J, Lebwohl M, Menter A

18. Kamili QU, Menter A. Topical treatment of psoriasis. Curr Probl Dermatol. 2009;38:37-58. Epub 2009 Jul 28 19. Ryan C, Bowcock AM, Menter A (2012). Psoriasis. Mloy S, Hughes Kelly (eds) Brenner’s Online Encyclopedia of Genetics, 2nd edition, in press. Academic Press BOOKS: 1. Fast Facts – Psoriasis. 2002 Edition of Health Press Limited. Smith C, Barker J, and Menter A.


2. Fast Facts – Psoriasis. 2004 Second Edition of Science Press Limited. Smith C, Barker J, and

Menter A.

3. Fast Facts – Psoriasis. 2008 Third Edition Health Press Limited. Menter A, Smith C, Barker J

4. Psoriasis. 2010 Manson Publishing, UK. Menter A, Stoff B. POSTER EXHIBITS: 1. Psoriasis day care therapy. Texas Medical Association, Austin, 1984.

2. Erythrodermic psoriasis: Precipitating factors, course and prognosis in 50 patients.

American Academy of Dermatology, Washington DC, 1988.

3. Oral manifestations of psoriasis. American Academy of Dermatology, Washington DC, 1988.

4. Immunologic evaluation of patients with psoriasis treated with cyclosporine A. American

Academy of Dermatology, San Francisco, CA 1989.

5. One-year, two-period study of the safety and efficacy of botulinum toxin type-A in patients with glabellar lines: Four-month double-blind vehicle-controlled period followed by an eight-month open-labeled period. American Academy of Dermatology, Washington DC, 2001.

6. Vehicle-controlled study of the efficacy and safety of botulinum toxin type-A in patients

with glabellar lines. American Academy of Dermatology, Washington DC, 2001-04-06.

7. Results of a multiple-dose, multiple-schedule trial of an anti-CD80 monoclonal antibody (IDEC-114) in patients with psoriasis. American Academy of Dermatology, Washington DC, 2001.

8. Immunophenotypic and functional analysis of skin-infiltrating lymphocytes of patients with

psoriasis. American Academy of Dermatology, San Francisco, CA, 1989.

9. Glofil follow-up in patients treated with low-dose cyclosporine A. American Academy of Dermatology, Atlanta, GA, 1990.

10. The annual cost of psoriasis care. American Academy of Dermatology, Atlanta, GA, 1990.

11. Hydroxyurea in psoriasis. American Academy of Dermatology, Atlanta, GA, 1990.

12. Annual cost of psoriasis treatment. 5th International Psoriasis Symposium, San Francisco,

CA, 1991.


13. Glofil follow-up in patients treated with low-dose cyclosporine A. 5th International

Psoriasis Symposium, San Francisco, CA, 1991.

14. Methotrexate and reproduction in men. American Academy of Dermatology, Dallas, TX, 1991.

15. Genetic association of HLA antigens with psoriasis. American Academy of Dermatology,

Dallas, TX, 1991.

16. Genetic linkage analysis in the study of psoriasis. American Academy of Dermatology, 1992.

17. Menter A, Prystowsky J, Lew-Kaya DA, Baker FD. Efficacy and tolerability of tazarotene

0.1% and 0.05% gels plus topical corticosteroids in patients with plaque psoriasis. American Academy of Dermatology, Orlando, FL, February 1998.

18. Lebwohl M, Bissonnette R, Ellis C, Gordon K, Gottlieb A, Gulliver W, Korman N,

Krueger G, Lowe N, Menter A, Papp K, Poulin Y, Washenik K, Rizova E. A randomized, double-blind, placebo-controlled phase III study to evaluate weekly intravenous bolus administration of alefacept in patients with chronic plaque psoriasis. 10th Congress of the European Academy of Dermatology and Venereology, Munich, Germany, October 2001.

19. Menter A, Stone SP, Swinehart J, Scannon M, Dummer W, Tyring S, Kaplowitz H, Lowe

N. Subcutaneous efalizumab (anti-CD11a) provides early symptomatic relief and continuous control of moderate to severe plaque psoriasis: Focus on pruritus. American Academy of Dermatology Summer Conference, New York, NY, July 31 – August 4, 2002.

20. Menter A, Parish LC, Ellis C. Safety of tolerability of repeat courses of alefacept in

patients with chronic plaque psoriasis. American Academy of Dermatology Summer Conference, New York, NY, July 31 – August 4, 2002.

21. Gottlieb AB, Shu L, Evans R, menter A. Infliximab in the treatment of psoriasis: results

from the first 10 weeks of the Phase II trial. American Academy of Dermatology 61st Annual Meeting, San Francisco, March 21-26, 2003.

22. Koo J, Menter A, Lebwohl M, Kozma C. The relationship between quality of life and

disease severity: results from alarge cohort mix, moderate to severe psoriasis patients. American Academy of Dermatology 61st Annual Meeting, San Francisco, March 21-26, 2003.

23. Koo J, Kozma C, Menter A, Lebwohl M. Development of the 12 item psoriasis quality of

life questionnaire (PQOL). American Academy of Dermatology 61st Annual Meeting, San Francisco, March 21-26, 2003.


24. Menter A, McCune M, Lynde C, Lebwohl M. Effects of efalizumab (anti-CD11a) on pruritus in subjects with moderate to severe psoriasis. American Academy of Dermatology 61st Annual Meeting, San Francisco, March 21-26, 2003.

25. Koo J, Menter A. The Koo-Menter instrument for identification of psoriasis patients

requiring systemic therapy. International Psoriasis Symposium, New York, NY, June 17-22, 2003.

26. Menter A. Efficacy and safety of clobetasol propionate 0.05% spray for the treatment of

moderate to severe plaque psoriasis involving up to 20% BSA

27. Marano CW, Evans R, Guzzo C, Menter A, Gottlieb AB, Li S, Wagner C. Immunogenicity of Infliximab (Remicade®) and its effect on safety and efficacy in patients with moderate-to-severe plaque-type psoriasis. International Psoriasis Symposium, New York, NY, June 17-22, 2003.

28. Leonardi C, Walicke P, Wang X, Compton P, Kaplowitz H, Menter A. No evidence for

increased risk of malignancy with efalizumab treatment. International Psoriasis Symposium, New York, NY, June 17-22, 2003.

29. Gordon K, Toth D, Papp K, Hamilton T, Walicke P, Li N, Menter A. Efalizumab provides

rapid and sustained clinical benefit for patients with moderate to severe plaque psoriasis. International Psoriasis Symposium, New York, NY, June 17-22, 2003.

30. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the

psoriasis area and severity index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. International Psoriasis Symposium, New York, NY, June 17-22, 2003.

31. Gottlieb AB, Evans R, Li S, Dooley L, Guzzo C, Menter A. The efficacy and safety of

infliximab induction therapy in patients with moderate to severe plaque-type psoriasis. International Psoriasis Symposium, New York, NY, June 17-22, 2003.

32. Gottlieb Evans R, Li S, Menter A. The efficacy and safety of infliximab induction therapy

in subjects with severe plaque-type psoriasis. International Psoriasis Symposium, New York, NY, June 17-22, 2003

33. Gottlieb AB, Li S, Evans R, Menter A. Infliximab in the treatment of psoriasis: Results

from the first 10 weeks of the Phase II trial. American Academy of Dermatology Summer Conference, San Francisco, CA 2003.

34. Zhu YW, Graham MA, Menter A, Gottlieb A. Pharmacokinetics of infliximab (Remicade)

in patients with severe plaque-type psoriasis. American Academy of Dermatology Summer Conference, San Francisco, CA 2003.


35. Chen DM, Gordon K, Leonardi C, Menter MA. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: Preliminary findings from a 12-week dose-ranging trial. P2. American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.

36. Tope WD, Menter A, El-Azhary RA, Lowe NJ. Comparison of topical

methylaminolevulinate photodynam,ic therapy versus placebo photodynamic therapy in noduar basal cell carcinoma. American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.

37. Menter A, Lew-Kaya D, Beddingfield F, Walker PS. A long-term, open-label study of the

safety and efficacy of oral tazarotene in moderate to very severe plaque psoriasis. P6. American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.

38. Schwartz L, Menter A, Weiss J, Clark SD. Calcitriol 3µG/G ointment in the treatment of

chronic plaque psoriasis. American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.

39. Menter A, Abramovits W, Cather J. Alefacept in combination with tapering doses of

methotrexate in patients with psoriasis. American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.

40. Menter A, Cather J. Long-term use of intravenous Alefacept: safety and off-treatment

responses in patients who have received four or more courses of therapy. American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.

41. Feldman SR, Bala M, Menter A, Gordon KB. The quality of life of patients with severe

psoriasis treated with infliximab. P7. American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.

42. Walker PS, Gottlieb A, Guenther L, Menter A. Safety of oral tazarotene in moderate to

severe plaque psoriasis. P595. American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.

43. Menter A, Hamilton T, Caro I, Chen-Rundle A. Impact of efalizumab on patient-reported

outcomes in patients with moderate to severe plaque psoriasis: pooled results from three randomized Phase III trials. American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.

44. Kang S, Menter A, Walker PS. Oral tazarotene and difficult-to-treat psoriatic lesions. P597.

American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.


45. Zhu Y, Graham M, Menter A, Gottlieb AB. Pharmacokinetics of infliximab in patients with severe plaque psoriasis. P617. American Academy of Dermatology 62nd Annual Meeting, Washington, DC, February 6-11, 2004.

46. Menter A, Kwon P, Leonardi C. Incidence and prevention of rebound upon abrupt

efalizumab discontinuation. International Psoriasis Symposium, Toronto, Canada, June 10-13, 2004.

47. Papp Ka, Caro I, Chastain R, Wang X, Menter A. The safety of continuous subcutaneous

efalizumab therapy for moderate to severe chronic plaque psoriasis: Preliminary results from an open-label, multicenter study. American Academy of Dermatology Summer Conference, New York, NY, July 28-August 1, 2004.

48. Menter A, Kardatzke D, Rundle AC, Kwon P, Garovoy MR, Leonardi CL. Incidence and

prevention of rebound upon efalizumab discontinuation. American Academy of Dermatology Summer Conference, New York, NY, July 28-August 1, 2004.

49. Menter A, Ticho B. Safety and off-treatment responses following multiple courses of

Alefacept in patients with chronic plaque psoriasis. American Academy of Dermatology Summer Conference, New York, NY, July 28-August 1, 2004.

50. Menter A, Baker D, Farber H, Lebwohl M. Long-term use of alefacept: Efficacy and off-

treatment responses in patients who have received multiple courses of therapy. American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

51. Menter MA, Gordon K, Leonardi C, Chen D. Adalimumab efficacy and safety results in

patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis. American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

52. Cather J, Menter A, Abramovits W. Adalimumab for psoriasis. American Academy of

Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

53. Cather J, Meier A, Winterfield L, Menter A. Clinical experience with alefacept and CD4+ T-cell counts. American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

54. Cather J, Meier A, Young M, Menter A. Clinical experience with alternate dosage

regimens of alefacept. American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

55. Cather J, Menter A. Considerations for oral acitretin combination therapy for psoriasis.

American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.


56. Feldman S, Menter A. Repeated courses of alefacept are cost-effective for the long-term management of psoriasis. American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

57. Menter A, Papp K. Safe psoriasis control: A new approach to evaluating the efficacy of

psoriasis treatments. American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

58. Menter A, Hamilton T, Papp K. Safety and tolerability of efalizumab therapy for patients

with moderate to severe chronic plaque psoriasis: Results of an open-label phase IIIb multicenter trial. American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

59. Cather J, Mann J, Abramovits W, Menter A. The safety of alefacept used in combination

with conventional systemic psoriasis therapies. American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

60. Cather J, Menter A, Young M, Wiatrowski M. The use of efalizumab in the clinic.

American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

61. Cather J, Menter A, Kelley A, Aponte C. The use of infliximab for psoriasis. American

Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

62. Cather J, Meier A, Young M, Menter A. Transitioning patients with psoriasis from conventional systemic psoriasis therapies to alefacept. American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

63. Cather J, Menter A, Wiatrowski M. The changing landscape of psoriasis. American

Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

64. Cather J, Menter A, Ghatrehee C, Munoz O. Diphenhydramine intraoral infraorbital nerve blocks prior to hyaluronic acid-based fillers. American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

65. Menter A. Long-term use of alefacept: efficacy in patients who have received multiple

courses of therapy. Canadian Dermatology Association 80th Annual Conference, Quebec City, Quebec, June 28-July 3, 2005.

66. Lebwohl M, Menter A. Efficacy and safety of alefacept in combination with methotrexate

in the treatment of psoriatic arthritis. P116. American Academy of Dermatology Summer Conference, Chicago, IL, July 20-24, 2005.

67. Gottlieb A, Feldman S, Weinstein G, Menter A. Infliximab phase III results: Every 8 week

versus as needed maintenance therapy. P131. American Academy of Dermatology Summer Conference, Chicago, IL, July 20-24, 2005.


68. Menter A, Lebwohl M, Ticho B. Efficacy and safety of up to three courses of intramuscular

alefacept. P-42. American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.

69. Gottlieb AB, Feldman S, Weinstein G, Menter A. Infliximab: One-year phase III results.

American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.

70. Gottlieb A, Hamilton T, Rafal E, Caro I, Baptista , Menter A. Safety and tolerability of

extended efalizumab therapy in patients with chronic moderate to severe plaque psoriasis. American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.

71. Stephens T, Tecco M, Menter A. A testing paradigm for evaluating the safety of a cosmetic

regimen for sensitive skin individuals. P-224. American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.

72. Menter A. Focal plantar hyperhidrosis: A review plus evaluation of a new fabric shoe liner.

P-565. American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.

73. Menter A, Jorizzo J, Vamvakias G. One-week treatment with 0.5% fluorouracil (FU) cream

in patients with actinic keratosis. P-2424. American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.

74. Menter A. Comparative efficacy of calcipotriene/betamethasone combination product after

1, 2, 4 weeks of treatment of mil, moderate, and severe psoriasis. P-2868. American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.

75. Menter A, Matheson R, Griffiths CEM, Li S. Consistency of response of infliximab

5mg/kg maintenance therapy: Data from EXPRESS and EXPRESS II. P-2878. American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.

76. Leonardi C, Menter A, Kimball A, Guzzo C. Infliximab for the treatment of moderate to

severe psoriasis: Response to re-treatment. P-2888. American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.

77. Menter A, Papp K, Guzzo C, Li S. Pooled efficacy of infliximab for the treatment of

patients with moderate to severe psoriasis. P-2899. American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.

78. Strober B, Menter A, Schear N, Searles G. Reduced T-cell monitoring schedules for

patients treated with alefacept. P-2903. American Academy of Dermatology 64th Annual Meeting. San Francisco, CA, March 3-7, 2006.


79. Brimhall AK, Jacobe HT, Menter A. Meta-analysis of efficacy and safety of alefacept, efalizumab, and etanercept for psoriasis. P-233. Society for Investigative Dermatology 67th Annual Meeting. Philadelphia, PA, May 3-6, 2006.

80. Menter A, Reich K, Li S, Guzzo C. Consistency of infliximab response in different body

regions for treatment of moderate to severe psoriasis: Results from controlled clinical trials. American Academy of Dermatology Feb 1-3, 2008

81. Menter A, Matheson R, Poulin Y, Willian MK. Improvements in patient global assessment

of disease severity, plaque psoriasis and psoriatic arthritis pain, and pruritus with adalimumab: Subanalysis of the first 16 weeks of reveal. American Academy of Dermatology Feb 1-3, 2008

82. Menter A, Cather J, Perlmutter A, Jaracz E,. Three years clinical experience with alefacept

in 200 patients with chronic plaque psoriasis. American Academy of Dermatology Feb 1-3, 2008

83. Menter A, Gottlieb AB, Li S, Guzzo C. Infliximab for the treatment of moderate to severe

psoriasis: Response to retreatment after 16 weeks or more between infusions. American Academy of Dermatology Feb 1-3, 2008

84. Revicki D, Menter A, Saurat J, Kaul M. Association between clinical response and health-

related quality of life outcomes for patients with moderate to severe psoriasis. American Academy of Dermatology Feb 1-3, 2008

85. Menter A. Efficacy and safety of clobetasol propionate 0.05% spray for the treatment of

plaque psoriasis involving up to 20% BSA. American Academy of Dermatology Feb 1-3, 2008

86. Papp K, Leonardi C, Lynde C, Ouellet JP, Toth D, Rosoph L, Carey W. Long-term efficacy

and safety outcomes of continuous use of Efalizumab in patients with moderate-to-severe chronic plaque psoriasis: Update at 30 months

87. Feldman SR, Koo j, Lebwohl M, Menter A. Overall results from the COBRA trial

(Community-Based Research Assessment) Investigating Clobetasol Propionate 0.05% spray

88. Menter A, Papp KA, Leonardi CL, Gu Y, Rozzo SJ. Short and long-term efficacy and

safety of adalimumab in a pivotal phase III study in adult patients with moderate to severe chronic plaque psoriasis

89. Menter A, Colon LE, Johnson LA, Gottschalk R. Results from a randomized study

comparing clobetasol propionate 0.05%spray to calcipotriene 0.005%, betamethasone dipropionate 0.064% ointment for the treatment of plaque psoriasis. American Academy of Dermatology Feb 1-3, 2008


90. Menter A, Papp K, Gu Y, Okun M. Adalimumab use in psoriasis patients with selected underlying co-morbidities has a favorable adverse event profile: results of REVEAL. American Academy of Dermatology Summer July 30-Aug 3, 2008

91. Menter A, Papp K, Gu Y, McIlraith M. Lessening the impact of psoriasis on health-related

quality of life with adalimumab: results from the REVEAL study. American Academy of Dermatology Summer July 30-Aug 3, 2008

92. Kimball AB, Reich K, Ortonne JP, Szapary P, Li S, Mrowietz U, Menter A, Langley R.

High prevalence and under-diagnosis of cardiovascular risk factors among psoriasis patients in a clinical trial population. EADV Paris September 17-20, 2008

93. Reich K, Szapary P, Yeilding N, Hsu MC, Li S, Mrowietz U, Kimball AB, Menter A.

Quantifying cardiovascular risk among patients with moderate to severe psoriasis. EADV Paris September 17-20, 2008

94. Griffiths C, Strober B, van de Kerkhof PCM, Ho V, Guzzo C, Yeilding N, Fidelus-Gort R,

Zhou B, Xia K, Menter A. A Phase 3, Multicenter, randomized Study Comparing Ustekinumab and Etanercept for the treatment of Moderate to Severe Plaque Psoriasis. EADV Paris September 17-20, 2008

95. Menter A, Papp K, Leonardi C, McIlraith M. Adalimumab response is consistent across

subgroups of patients with moderate to severe psoriasis: results of REVEAL. EADV Paris September 17-20, 2008

96. Reich K, Prinz J, Szapary P, Yeilding N, Hsu MC, Li S, Mrowietz U, Kimball AB, Menter

A. Quantifying Cardiovascular Risk Among Patients with Moderate to Severe Psoriasis. Gene to Clinic Dec 3-7 2008

97. Griffiths C, Menter A, Strober B, Fidelus-Gort R. A phase 3, multicenter,r andomized

study comparing Ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis. 67th AAD, San Francisco, March 5 - 10/2009

98. Menter A, Signorovitch J, Mulani P, Gupta S. Adalimumab reduces symptoms of

depression in patients with moderate to severe psoriasis. 67th AAD, San Francisco, March 5 - 10/2009

99. Menter A, Gordon K, Goldblum O, Gu. Efficacy and safety of adalimumab are consistent

across weight quartiles in patients with moderate to severe psoriasis: subanalysis of REVEAL. 67th AAD, San Francisco, March 5 - 10/2009

100. Menter A, Sasso E, Gu. Relationship between effectiveness of starting adalimumab and

degree of psoriasis activity after a period of discontinuation. 67th AAD, San Francisco, March 5 - 10/2009


101. Menter A, Wu, Mulani, Gupta. Discontinuation of adalimumab treatment for psoriasis following sustained response: effects on health-related quality of life. 67th AAD, San Francisco, March 5 - 10/2009

102. Horn EJ, Barker J, Langley R, Menter A, Kimball AB. Quality of care and research profiles:

results of an International Psoriasis Council (IPC) exercise. 2nd World Conference on Psoriasis, Stockholm, Sweden, June 25-28, 2009

103. Langley R, Kimball A, Menter A, Gordon K, Valdes J. Effect of Baseline Characteristics on

the Efficacy of ABT-874 for the Treatment of Moderate to Severe Psoriasis. Fall EADV Berlin, 2009

104. Menter A, Kimball A, Langley R, Gordon K, Valdes J. Efficacy of Treatment With ABT-

874, an Interleukin-12/23 Monoclonal Antibody, Across Body Regions of Patients with Moderate to Severe Psoriasis. Fall EADV Berlin 2009

105. Leonardi C, Menter A, Ghislain PD, Wasel N, Poulin Y, Fakharzadeh S, Shu L, Yeilding

N, Thomas J, Courtney T, Wilkosz D, Suh B. Maintenance of long-term efficacy of ustekinumab through year 3 for patients with moderate-to-severe psoriasis. P589, Fall EADV Gothenburg 2010

106. Menter A, Papp K, Crowley J, Gu Y, Saso E. Long-term outcomes of interruption and

retreatment vs continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL. Summer AAD 2011 NYC

107. Gupta P, Hutmacher M, Tan H, Harness J, Menter A, Strober B, Langley RG, Papp KA,

Krishnaswami S. The influence of body weight on the efficacy of Tofacitinib (CP-690,550) in patients with plaque psoriasis. Seoul WCD May 24-29, 2011

108. Mamolo C, Tan H, Li J, Menter A, Strober B, Langley RG, Papp KA, Harness J. The effect of tofacitinib (CB-690,550), an oral Janus Kinase inhibitor, on pain and discomfort associated with psoriasis. Seoul WCD May 24-29, 2011

109. Kimball A, Bissonnette R, Leonardi C, Menter A, Szapary PO, Wasfi Y, Ott E, Hsu M, van de Kerkhof P, Reich K. Infection rates in the Ustekinumab psoriasis clinical trial program: update with up to 4 years of follow up. EADV 2011 Oct 20-24, Lisbon, Portugal

110. Menter A, Hornbeck LJ, Gourgouliatos Z. Home based targeted Ultraviolet B phototherapy – patient experience and clearance rates. EADV 2011 Oct 20-24, Lisbon, Portugal

111. Papp KA, Leonardi C, Menter A, Ortonne JP, Kricorian G, Aras G, Li J, Thompson EHZ, Baumgartner S. Efficacy and safety of AMG 827 in subjects with moderate to severe plaque psoriasis: results of a Phase 2, randomized, double-blind, placebo-controlled study. EADV 2011 Oct 20-24, Lisbon, Portugal


BOOK REVIEWS: 1. Handbook of Skin Clues of Systemic Disease, NY State J Med 1991. 2. Psoriasis, Cambridge, MA, Blackwell Scientific Publications, 1994, in J Am Acad Dermatol.

May 1997:806. 3. Dermatology DDx Deck, Habif TP, Campbell Jr JL, Chapman MS, Dinulos JGH, Zug KA.

Philadelphia, PA, Mosby Elsevier, 2006, in Proc (Bayl Univ Med Cent) 2007:20:89. RESEARCH GRANTS (As of July 2008 include funding from): 1. Abbott Laboratories 2. Allergan, Inc. 3. Allermed 4. Amgen, Inc. 5. Asubio 6. Berlex, Inc. 7. Biogen Idec 8. Centocor, Inc. 9. Cephalon 10. Celgene 11. Collagenex Pharmaceuticals 12. CombinatoRx 13. Connetics Corporation 14. Corixa Corporation 15. Dermik Laboratories 16. Doak Dermatologics 17. Dow 18. DUSA 19. Eli Lilly 20. Ferndale Laboratories, Inc. 21. Fujisawa Healthcare, Inc. 22. Galderma 23. Genentech, Inc. 24. Genzyme 25. GlaxoSmithKline 26. Ligand Pharmaceuticals 27. Medicis 28. MedImmune, Inc. 29. Novartis Pharmaceuticals 30. Otsuka Pharmaceutical, Inc. 31. Pfizer 32. Promius Pharma 33. Protein Design Labs


34. QLT, USA 35. Regeneration Pharma AG 36. Roche Laboratories 37. Serono 38. Sinclair 39. Stiefel 40. Synta Pharma 41. Thermosurgery 42. 3 M Pharmaceuticals 43. UCB 44. Vertex 45. Warner Chilcott 46. Wyeth 47. XOMA 48. Zars, Inc. Pending research grants: Novo Norsdisk No financial holdings in any Pharmaceutical Company.

alan menter, m.d. - dallas dermatologistalan menter, md – cv 5 1991-1998 dermatological...

Documents